David Mayers has over 28 years of pharmaceutical leadership experience in large multinational firms and small privately held organisations, and extensive experience in corporate strategy and oversight, research and development, quality, lean sigma, production, supply chain, procurement, information technology, finance, product development, product launch, facility expansion, security and the management of controlled substances. Starting his career as a chemist for SmithKline Beecham (now GlaxoSmithKline), Mr Mayers progressed through roles of increasing responsibility for Taro Pharmaceutical Industries, Merck KGaA, Apotex, and Purdue Pharma (Canada). He was chief operating officer and board member of Impopharma, a pharmaceutical company specialising in the development and launch of pulmonary and nasal inhalation pharmaceutical products, where he led a turnaround of the company’s R&D programs and facilitated its acquisition. Mr Mayers received his Bachelor of Science (with Honours) in Biological Science from the University of Guelph, and an MBA from the Rotman School of Business, University of Toronto.
